KARDIGAN INC (KARD) is drawing unusual attention today. Our newswire has captured 1 story on KARD across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
KARD stock fell 6.71% to $20.45 on Tuesday as the company reported disappointing Q2 earnings and faced mixed coverage from analysts. The stock opened at $21.96 but fell throughout the session, hitting a low of $20.43 before closing near that level. The decline followed a report that Kardigan posted Q2 EPS of $(4.61), well below the estimated $(0.71), signaling ongoing financial challenges for the company.
Kardigan announced second-quarter earnings of $(4.61) per share, missing the consensus estimate of $(0.71). This marked a significant shortfall and reinforced concerns about the company’s profitability. Despite recent analyst activity, TD Cowen initiated coverage with a Buy rating and a $46 price target, and Leerink Partners also issued an Outperform rating with a $37 price target, JP Morgan lowered its price target to $46 while maintaining an Overweight stance. These developments highlight a divergence in analyst sentiment but did not provide enough support to counter the earnings disappointment. Meanwhile, Kardigan is preparing to present at two investor conferences in September, with its Sept. 9 presentation potentially webcast live.
The stock opened at $21.96 and reached an intraday high of $22.21 before declining sharply. Volume remained light at 0.1M shares. The 52-week range is $16.25 to $27.00, and the stock has printed 14 fresh 52-week lows on September 3, 2026. Insiders, including Arch Venture Partners and Paul Berns, have made significant purchases totaling $90.0M in the last 90 days, indicating continued confidence from key stakeholders.
Kardigan has no upcoming earnings report scheduled. Investors should monitor the breadth of analyst coverage and the company’s performance at its September investor conferences for potential catalysts.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Kardigan outlook: biology-driven programs for genetic DCM, CAVS & ASH; $660.7M runway; and key 2027 catalysts. Click for more on KARD stock.
KARDIGAN INC (KARD) is drawing unusual attention today. Our newswire has captured 1 story on KARD across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 63/100). The most recent driver: "Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification" (Seeking Alpha).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of KARD coverage reads 63/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on KARD: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier KARD move explainers: 2026-09-03 · 2026-09-02